Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

rapamycin in islet transplantation: friend or foe?

Academic Article
Publication Date:
2009
abstract:
The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.
Iris type:
1.1 Articolo in rivista
List of contributors:
T., Berney; Secchi, Antonio
Handle:
https://iris.unisr.it/handle/20.500.11768/619
Published in:
TRANSPLANT INTERNATIONAL
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.0.0